Global Metabolic Disorder Therapeutics Market Report By Product (Metachromatic Leukodystrophy, Globoid Leukodystrophy, Hepatic Encephalopathy, And Others), Disease (Diabetes, Obesity, Hypercholesterolemia, And Lysosomal Storage Diseases), And By Regions - Industry Trends, Size, Share, Growth, Estimation And Forecast, 2018-2025
ID:VMR11210578
February 2019
Report Formats:

As per this study the Global Metabolic Disorder Therapeutics Market was valued USD XX.X MN (by revenue) in 2018 and is anticipated to reach USD XX.X MN by 2025 with a CAGR of X.X%.

Metabolism is a process in a digestive system where the food is broken down into glucose, amino acids, and fatty acids. A metabolic disorder is a condition when the body is unable to process metabolism and it can be caused due to unhealthy eating lifestyle. A metabolic disorder is either inherited genetically or acquired during the lifetime. Some metabolic disorders show mild symptoms that can be managed with slight medication whereas high symptoms such as breathing problems, organ failures, diabetes and others can be life-threatening. The treatment for this disorder can be done by enzyme replacement therapy, drug therapy, and others through oral and other administrations.
 
Market Dynamics
 
The rising incidences of obesity, diabetes and high cholesterol among the population is fueling the global metabolism market growth. Also, an increasing prevalence of unhealthy lifestyle diseases which leads to various digestive issues is also stimulating the market growth. On the flip side, the high cost of treatment for metabolic disorder is expected to restrain market growth.
 
This detailed market study is centered on the data obtained from multiple sources and is analyzed using numerous tools including porter’s five forces analysis, market attractiveness analysis and value chain analysis. These tools are employed to gain insights of the potential value of the market facilitating the business strategists with the latest growth opportunities. Additionally, these tools also provide a detailed analysis of each application/product segment in the global market of metabolic disorder therapeutics.
 
Market Segmentation
 
The broad metabolic disorder therapeutics market has been sub-grouped into product and disease. The report studies these subsets with respect to the geographical segmentation. The strategists can gain a detailed insight and devise appropriate strategies to target specific market. This detail will lead to a focused approach leading to identification of better opportunities.
 
By Product

  • Metachromatic Leukodystrophy
  • Globoid Leukodystrophy
  • Hepatic Encephalopathy
  • Others
 
By Disease
  • Diabetes
  • Obesity
  • Hypercholesterolemia
  • Lysosomal Storage Diseases
 
Regional Analysis
 
Furthermore, the report comprises of the geographical segmentation which mainly focuses on current and forecast demand for metabolic disorder therapeutics in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. The report further focuses on demand for individual application segments in all the regions.
 
Europe Metabolic Disorder Therapeutics Market By Revenue (USD MN)

Europe Metabolic Disorder Therapeutics Market By Revenue

The report also covers detailed competitive landscape including company profiles of key players operating in the global market. The key players in the Metabolic Disorder Therapeutics market include AbbVie Inc., Actelion Pharmaceuticals Ltd., AstraZeneca, Biocon, Boehringer Ingelheim, CymaBay Therapeutics, Eli Lilly and Company, Merck KgaA, Novo Nordisk, and Sanofi. An in-depth view of the competitive outlook includes future capacities, key mergers & acquisitions, financial overview, partnerships, collaborations, new product launches, new product developments and other developments with information in terms of H.Q.
 
 
METHODOLOGY:
 
A combination of primary and secondary research has been used to determine the market estimates and forecasts. Sources used for secondary research include (but not limited to) Paid Data Sources, Company Websites, Technical Journals, Annual Reports, SEC Filings and various other industry publications. Specific details on methodology used for this report can be provided on demand.

1. INTRODUCTION

  • Introduction To Metabolic Disorder Therapeutics
  • Report Description
    • Objectives Of The Study
    • Assumptions
  • Research Scope
  • Research Methodology
    • Data Source
 
2. EXECUTIVE SUMMARY
  • Market Highlight
  • Global Metabolic Disorder Therapeutics Market: Snapshot
 
3. MARKET ANALYSIS
  • Drivers
  • Restraints
  • Opportunities
  • Porter’s Five Forces Analysis
  • Value Chain Analysis
 
4. METABOLIC DISORDER THERAPEUTICS MARKET ANALYSIS BY PRODUCT
  • Metabolic Disorder Therapeutics Market In Metachromatic Leukodystrophy
  • Metabolic Disorder Therapeutics Market In Globoid Leukodystrophy
  • Metabolic Disorder Therapeutics Market In Hepatic Encephalopathy
  • Metabolic Disorder Therapeutics Market In Others
 
5. METABOLIC DISORDER THERAPEUTICS MARKET ANALYSIS BY DISEASE
  • Metabolic Disorder Therapeutics Market In Diabetes
  • Metabolic Disorder Therapeutics Market In Obesity
  • Metabolic Disorder Therapeutics Market In Hypercholesterolemia
  • Metabolic Disorder Therapeutics Market In Lysosomal Storage Diseases
 
6. METABOLIC DISORDER THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY
  • North America (NA)
    • North America Market Estimates
    • North America Market Estimates By Country
    • United States (U.S.) Market Estimates By Segments
    • Rest Of North America Market Estimates By Segments
  • Europe (EU)
    • Europe Market Estimates
    • Europe Market Estimates By Country
    • United Kingdom (UK) Market Estimates By Segments
    • Germany Market Estimates By Segments
    • France Market Estimates By Segments
    • Rest Of Europe Market Estimates By Segments
  • Asia Pacific (APAC)
    • Asia Pacific Market Estimates
    • Asia Pacific Market Estimates By Country  
    • China Market Estimates By Segments
    • Japan Market Estimates By Segments
    • India Market Estimates By Segments
    • Rest Of Asia Pacific Market Estimates By Segments  
  • Latin America (LA)   
    • Latin America Market Estimates
    • Latin America Market Estimates By Country
    • Brazil Market Estimates By Segments
    • Rest Of Latin America Market Estimates By Segments
  • Middle East And Africa (MEA)   
    • Middle East And Africa Market Estimates
    • Middle East And Africa Market Estimates By Country
    • Middle East Market Estimates By Segments
    • Africa Market Estimates By Segments
 
7. COMPETITIVE LANDSCAPE OF THE METABOLIC DISORDER THERAPEUTICS COMPANIES
  • Market Competition
  • Partnerships/Collaborations/Agreements
  • Mergers And Acquisitions
  • New Product Launches
  • Other Developments
 
8. COMPANY PROFILES OF THE METABOLIC DISORDER THERAPEUTICS INDUSTRY (Company Overview, Financial, Major Products & Recent Development)
  • AbbVie Inc.
  • Actelion Pharmaceuticals Ltd.
  • AstraZeneca
  • Biocon
  • Boehringer Ingelheim
  • CymaBay Therapeutics
  • Eli Lilly and Company
  • Merck KgaA
  • Novo Nordisk
  • Sanofi
 
* Tentative TOC
 
LIST OF TABLES
 
Table 1.  Market Highlights Of Metabolic Disorder Therapeutics
Table 2.  Global Metabolic Disorder Therapeutics Market By Product
Table 3.  Global Metabolic Disorder Therapeutics Market By Disease
Table 4.  Global Metabolic Disorder Therapeutics Market By Geography
Table 5.  North America Metabolic Disorder Therapeutics Market
Table 6.  Europe Metabolic Disorder Therapeutics Market
Table 7.  Asia Pacific Metabolic Disorder Therapeutics Market
Table 8.  Latin America Metabolic Disorder Therapeutics Market
Table 9.  Middle East And Africa Metabolic Disorder Therapeutics Market 
Table 10. Partnership/Collaboration/Agreements
Table 11. Mergers And Acquisitions
Table 12. New Product Development
Table 13. Other Developments
  
LIST OF FIGURES
 
Fig. 1.     Market Segmentation Of Metabolic Disorder Therapeutics Market 
Fig. 2.     Top-Down Approach   
Fig. 3.     Bottom-Up Approach   
Fig. 4.     Market Highlights Of Metabolic Disorder Therapeutics
Fig. 5.     Porter’s Five Forces Analysis
Fig. 6.     Value Chain Analysis
Fig. 7.     Global Metabolic Disorder Therapeutics Market By Product
Fig. 8.     Global Metabolic Disorder Therapeutics Market By Disease
Fig. 9.     Global Metabolic Disorder Therapeutics Market By Geography
Fig. 10.   North America Metabolic Disorder Therapeutics Market
Fig. 11.   Europe Metabolic Disorder Therapeutics Market
Fig. 12.   Asia Pacific Metabolic Disorder Therapeutics Market
Fig. 13.   Latin America Metabolic Disorder Therapeutics Market
Fig. 14.   Middle East And Africa Metabolic Disorder Therapeutics Market
Fig. 15.   Market Share Of Metabolic Disorder Therapeutics Companies
Fig. 16.   Recent Developments In Metabolic Disorder Therapeutics Industry
 
 
* Kindly note that the above listed are the basic tables and figures of the report and are not limited to the TOC. 

Objectives of Study

  • Define and measure the global market
  • Volume or revenue forecast of the global market and its various sub-segments with respect to main geographies
  • Analyze and identify major market trends along with the factors driving or inhibiting the market growth
  • Study the company profiles of the major market players with their market share
  • Analyze competitive developments

Buy Chapters or Sections

Avail customized purchase options to meet your exact research needs:

  • Buy sections of this report
  • Buy country level reports
  • Request for historical data
  • Request discounts available for Start-Ups & Universities

Why Choose Us

Client First Policy
Excellent Quality
Robust After Sales Support
24/7 Email Support

Clients

Testimonials